Search clinical trials for: Tislelizumab plus Fruquintinib and SBRT

Total 4676 results

Peking University Cancer Hospital & Institute

Recruiting

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

Liver Metastasis Colon Cancer | Advanced Colorectal Carcinoma

China
National Taiwan University Hospital

Not yet recruiting

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

Unresectable Hepatocellular Carcinoma | Pembrolizumab | Stereotactic Body Radiotherapy | Lenvatinib

Taiwan
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Hepatocellular Carcinoma

China
Daping Hospital and the Research Institute of Surgery...

Recruiting

PPIO-008S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY

Postoperative Assistance for Esophageal Squamous Cell Carcinoma With Negative Lymph Nodes

China
The First Affiliated Hospital of Xinxiang Medical...
BeiGene

Not yet recruiting

Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma

ESCC
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Small Cell Lung Carcinoma

China
BeiGene

Terminated

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

Advanced Solid Tumors

Australia, Spain, New Zealand
Hutchison Medipharma Limited
Sun Yat-sen University

Active, not recruiting

A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) (FRUTIGA)

Advanced Gastric Cancer

China
Emory University

Completed

Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, Pancreatic

United States
CCTU

Recruiting

SRAM study_Postate Cancer

Advanced Prostate Cancer

Hong Kong
Rigshospitalet, Denmark

Recruiting

Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver

Liver Metastases | Colorectal Carcinoma

Denmark
Kidney Cancer Research Bureau

Completed

Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO Therapy

Metastatic Renal Cell Carcinoma

Russian Federation
UNICANCER

Withdrawn

Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer (OLIVER)

Colorectal Cancer | Liver Metastases
Zhejiang Cancer Hospital

Recruiting

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

NSCLC Stage IV

China
Accuray Incorporated
Centre Oscar Lambret

Terminated

CyberKnife® for Hepatic Metastases From Colorectal Cancer

Colorectal Liver Metastases

France, Germany, United Kingdom
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Henan Cancer Hospital

Recruiting

PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma

Advanced Melanoma

China
Yanhong Deng

Recruiting

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer (CAMCO2)

Metastatic Colorectal Cancer，NED

China
Bern University of Applied Sciences
Goethe University; Maastricht University Medical Center; Swiss Federal Institute...

Completed

Application of Whole-body Vibration With Stochastic Resonance in Frail Elderly: The Effects on Postural Control

Equilibration Disorder, Vestibular Nerve

Switzerland
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

Small-cell Lung Cancer

China
Canadian Cancer Trials Group
NRG Oncology

Recruiting

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment (ASCENDE-SBRT)

Prostate Cancer

Canada
Sun Yat-sen University

Recruiting

SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx

SBRT

China
McMaster University

Recruiting

Post SBRT Pulmonary Metastasectomy (PSPM) Trial (PSPM)

Lung Cancer | Stereotactic Body Radiotherapy | Surgical Resection | Pulmonary Metastasectomy

Canada
University of Sao Paulo

Active, not recruiting

SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE

Carcinoma, Hepatocellular

Brazil
Galera Therapeutics, Inc.

Terminated

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC (GRECO-1)

NSCLC | SBRT | Non-metastatic

United States
Beijing Friendship Hospital
Changhai Hospital; The First Affiliated Hospital of Anhui Medical University; Fudan University and other collaborators

Recruiting

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study

Locally Advanced Rectal Carcinoma

China
Fudan University

Recruiting

Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma (RETICULA-NPC)

Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Unresectable Nasopharyngeal Carcinoma | Stereotactic Body Radiation Therapy (SBRT)

China
Zhejiang Cancer Hospital

Recruiting

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Biliary Tract Carcinoma

China
Xijing Hospital

Recruiting

Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Stichting Hemato-Oncologie voor Volwassenen Nederland
Danish Lymphoma Group

Recruiting

Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (HOVON164HL)

Hodgkin Lymphoma

Netherlands, Belgium, Denmark
Changhai Hospital

Recruiting

Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer

Treatment

China
Instituto de Investigación en Oncología Radioterápica...
Instituto de Investigación en Oncología Radioterápica FEOR (IRAD-FEOR)

Recruiting

START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC (START-MET)

Prostate Cancer | Stereotactic Body Radiation Therapy

Spain
RWTH Aachen University

Not yet recruiting

Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma (ASTrH)

Hepatocellular Carcinoma Non-resectable
Base Therapeutics (Shanghai) Co., Ltd.
Shanghai 10th People's Hospital

Enrolling by invitation

Safety and Efficacy of NK510 to Treat Gastric Cancer

Gastric Cancer

China
Base Therapeutics (Shanghai) Co., Ltd.
The General Hospital of Eastern Theater Command

Recruiting

Safety and Efficacy of NK510 to Treat NSCLC

NSCLC

China
Qure Healthcare, LLC
Lineagen

Completed

Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study

Intellectual Disability | Developmental Delay

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

China
M.D. Anderson Cancer Center

Terminated

Metformin in Non Small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
IRCCS San Raffaele

Recruiting

24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer (PRO-FAST)

Localized Prostate Carcinoma

Italy
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

Prostate Cancer

United States
National Cancer Centre, Singapore
Tan Tock Seng Hospital; BeiGene

Not yet recruiting

Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Singapore
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Head and Neck Squamous Cell Carcinomas

China
Zhejiang Cancer Hospital

Recruiting

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

Extensive Stage Small Cell Lung Cancer

China
Zhejiang Cancer Hospital

Recruiting

GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence (GOT)

Intrahepatic Cholangiocarcinoma

China
Tianjin Medical University Second Hospital

Recruiting

Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)

Neoadjuvant Immunotherapy

China
Genor Biopharma Co., Ltd.
Hutchison Medipharma Limited

Unknown

Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
University of Cologne

Not yet recruiting

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE)

Classical Hodgkin Lymphoma

Germany
Shanghai General Hospital, Shanghai Jiao Tong University...

Not yet recruiting

Study of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer

Colorectal Carcinoma
Guangxi Medical University

Completed

HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC (FRONT-1)

Liver Cancer

China
Qilu Hospital of Shandong University

Not yet recruiting

First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer (RCTS)

HER2-positive Gastric Cancer

China

3

Subscribe